Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Margin expansion as labor markets stabilize, driving outsized FCF and accelerated share repurchases, propelling valuation toward the $798 high band.
HCA Healthcare is a dominant, scale-advantaged hospital operator executing a classic mature compounder playbook. The company leverages demographic tailwinds and local market density to maintain industry-leading 15% margins, generating robust free cash flow ($7.6B+) that is aggressively deployed toward capacity expansion and share repurchases.
HCA Healthcare is a dominant, scale-advantaged hospital operator executing a classic mature compounder playbook. The company leverages demographic tailwinds and local market density to maintain industry-leading 15% margins, generating robust free cash flow ($7.6B+) that is aggressively deployed toward capacity expansion and share repurchases.
Local market density and scale advantages driving industry-leading margins.
Demographic tailwinds with an aging population ensuring consistent volume.
Market under-appreciates the durability of HCA's local market density and the resultant ROIC/WACC spread.
Strong Buy based on structural margin durability and aggressive yield-accretive buybacks driving a composite fair value of $647.26.
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
A prolonged period of elevated interest rates combined with flat commercial volumes and margin compression to 13% would severely stress HCA's free cash flow, threatening the heavily leveraged capital structure and ending the share repurchase algorithm.
Local market density and scale advantages driving industry-leading margins.
Demographic tailwinds with an aging population ensuring consistent volume.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $8.2B after capex $4.9B, with terminal value at 71.8% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
Margin expansion as labor markets stabilize, driving outsized and accelerated share repurchases, propelling valuation toward the $798 high band.
If margins hold above 15% and buybacks exceed $2B/quarter, maintain Strong Buy. If margins compress below 14% or labor inflation spikes, pivot to Hold.
If margins hold above 15% and buybacks exceed $2B/quarter, maintain Strong Buy. If margins compress below 14% or labor inflation spikes, pivot to Hold.
If margins hold above 15% and buybacks exceed $2B/quarter, maintain Strong Buy. If margins compress below 14% or labor inflation spikes, pivot to Hold.
If margins hold above 15% and buybacks exceed $2B/quarter, maintain Strong Buy. If margins compress below 14% or labor inflation spikes, pivot to Hold.
Heavy reinvestment phase (capex $4.9B) funded internally by immense operating cash flow, sustaining moat.
Aging demographics and aggressive outpatient facility expansion driving commercial volumes.
Regulatory uncertainty, labor constraints, and rising financing costs.
Heavy reinvestment phase (capex $4.9B) funded internally by immense operating cash flow, sustaining moat.
Core holding given high intrinsic value predictability, but massive debt warrants active risk monitoring.
Reduce exposure if operating margins decisively break below 14% or if share outstanding reduction falls below 3% annually.
Strong Buy based on deterministic cash flow evidence and massive FCF conversion.
Downside case: Market under-appreciates the durability of HCA's local market density and the resultant ROIC/WACC spread.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Structural labor inflation and reimbursement cuts compress margins below 14%, while high leverage drags down the buyback strategy, dropping value to $496.
Government payers drastically compress Medicare/Medicaid rates to manage ballooning deficits, crushing margins.
Persistent clinical staff shortages force a permanent reliance on expensive contract labor, eroding operating margins below 14%.
Refinancing the massive $48.7B net debt load at significantly higher rates extinguishes the aggressive buyback program.
The five developments that would weaken our investment case.
Squeezed hospital margins reflect severe operational cost pressures and unfavorable payer reimbursement trends. Breaching this baseline erodes operating income, leaving less operating cash flow to service debt obligations and sustain capital expenditures in core geographic hospital networks.
Current:15.8% for the period ended 2025-12-31
Alert ifOperating margin falls below 14.0% over two consecutive quarters
Deceleration of share repurchases dismantles the core financial algorithm that drives double-digit EPS growth independently of volume gains. Slower share reduction forces earnings per share expansion to rely entirely on organic net income, reducing overall return on equity.
Current:Active share repurchase program exceeding 3% annual share reduction as of 2026-05-13
Alert ifAnnual reduction in diluted shares outstanding falls below 3.0% over a twelve-month period
Inability to fill nursing and clinical vacancies with permanent employees drives reliance on high-cost premium agency staffing. Accelerated wage expense severely compresses hospital operating margins, reducing cash flow needed for facility modernization and capacity additions.
Current:Manageable clinical staffing utilization as of 2026-05-13
Alert ifContract labor costs increase by more than 15% year-over-year over two consecutive quarters
An unfavorable payer mix shift reduces realized revenue per adjusted admission because government programs reimburse at significantly lower rates than private commercial insurance. Lower reimbursement rates undermine facility profitability and diminish overall return on invested capital across regional hospital networks.
Current:Favorable commercial insured volume baseline as of 2026-05-13
Alert ifCommercial admissions decline by more than 2.0% year-over-year while Medicaid or uninsured volume increases
Inadequate cash flow conversion strains the company's leveraged balance sheet and limits capital deployment toward hospital acquisitions and routine facility expansions. Diminished cash generation leaves insufficient liquidity to maintain the aggressive share repurchase program without expanding leverage beyond target ratios.
Current:$7.7B annual free cash flow for the period ended 2025-12-31
Alert ifFree cash flow generation falls below $7.0B over an annual period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Continued execution of the mature compounder playbook. Steady 15% margins, reliable FCF generation, and consistent buybacks yield a $647 mid-point.
Warning level: Operating margin falls below 14.0% over two consecutive quarters. Squeezed hospital margins reflect severe operational cost pressures and unfavorable payer reimbursement trends. Breaching this baseline erodes operating income, leaving less operating cash flow to service debt obligations and sustain capital expenditures in core geographic hospital networks.
Warning level: Annual reduction in diluted shares outstanding falls below 3.0% over a twelve-month period. Deceleration of share repurchases dismantles the core financial algorithm that drives double-digit EPS growth independently of volume gains. Slower share reduction forces earnings per share expansion to rely entirely on organic net income, reducing overall return on equity.
Warning level: Contract labor costs increase by more than 15% year-over-year over two consecutive quarters. Inability to fill nursing and clinical vacancies with permanent employees drives reliance on high-cost premium agency staffing. Accelerated wage expense severely compresses hospital operating margins, reducing cash flow needed for facility modernization and capacity additions.
Warning level: Commercial admissions decline by more than 2.0% year-over-year while Medicaid or uninsured volume increases. An unfavorable payer mix shift reduces realized revenue per adjusted admission because government programs reimburse at significantly lower rates than private commercial insurance. Lower reimbursement rates undermine facility profitability and diminish overall return on invested capital across regional hospital networks.
Warning level: Free cash flow generation falls below $7.0B over an annual period. Inadequate cash flow conversion strains the company's leveraged balance sheet and limits capital deployment toward hospital acquisitions and routine facility expansions. Diminished cash generation leaves insufficient liquidity to maintain the aggressive share repurchase program without expanding leverage beyond target ratios.
| — |
| $60.23B |
| $64.97B |
| $70.60B |
| $75.60B |
| +7.9% |
| Gross profit | — | $23.18B | $25.58B | $28.68B | $31.37B | +10.6% |
| Operating income | — | $10.32B | $9.64B | $10.58B | $12.08B | +5.4% |
| Net income | — | $5.64B | $5.24B | $5.76B | $6.78B | +6.3% |
| EPS (diluted) | — | $19.15 | $18.97 | $22.00 | $28.33 | +13.9% |
| EBITDA | — | $13.29B | $12.72B | $13.90B | $15.60B | +5.5% |
| R&D | — | — | — | — | — | — |
| SG&A | $26.78B | $27.69B | $29.49B | $31.17B | — | +5.2% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 75,600,000,000 |
|---|---|
| Cost of revenue | 44,226,000,000 |
| Gross profit | 31,374,000,000 |
| Operating expenses | 19,409,000,000 |
| Operating income | 11,965,000,000 |
| Non-operating items and tax | -5,181,000,000 |
| Net income | 6,784,000,000 |
Point-in-time financial data used in the 2026-05-13 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | 60.2B | 13.3B | 5.6B | 8.5B | 4.1B | 4.4B | 3B | 341M | 7B | 653M | 3.3B | — | — | — | — | 908M | 40.2B | 15.0% | — | 7.3% | — |
| 2023-12-31 | 65B | 12.7B | 5.2B | 9.4B | 4.7B | 4.7B | 3.1B | 262M | 3.8B | 661M | 1.3B | — | — | — | — | 935M | 41.9B | 14.8% | — | 7.3% | — |
| 2024-12-31 | 70.6B | 13.9B | 5.8B | 10.5B | 5.6B | 4.9B | 3.3B | 360M | 6B | 690M | 3.2B | — | — | — | — | 1.9B | 45.2B | 14.9% | — | 7.8% | — |
| 2025-12-31 | 75.6B | 15.6B | 6.8B | 12.6B | 7.7B | 4.9B | 3.5B | 401M | 10.1B | 679M | 3.3B | — | — | — | — | 1B | 48.7B | 15.8% | — | 6.4% | — |
HCA trades at 12.9x forward earnings against a peer median of 12.8x; EV/EBITDA of 9.4x against a peer median of 14.1x; 6 peers.
| Universal Health Services Inc. |
| 6.6x |
| 0.6x |
| 5.7x |
| 21.4% |
| 11.2% |
| LLY | Eli Lilly and Company | 21.8x | 11.9x | 24.9x | 107.5% | 49.4% |
| JNJ | Johnson & Johnson | 17.4x | 5.5x | 16.5x | 26.4% | 27.4% |
| ABBV | AbbVie Inc. | 12.8x | 5.8x | 14.1x | 62.2% | 32.2% |
